693 | Humans |
511 | Female |
410 | Male |
393 | Adult |
275 | Adolescent |
266 | Ghana |
235 | Middle Aged |
216 | Ghana (epidemiology) |
151 | Young Adult |
144 | HIV Infections (epidemiology) |
128 | HIV Infections (prevention & control) |
118 | Child |
112 | Cross-Sectional Studies |
111 | Prevalence |
95 | Health Knowledge, Attitudes, Practice |
88 | Risk Factors |
86 | Developing Countries |
85 | HIV Infections (drug therapy) |
82 | Infant |
78 | Pregnancy |
77 | HIV Infections (transmission) |
76 | Child, Preschool |
72 | HIV Infections (complications) |
71 | Aged |
66 | HIV Infections (psychology) |
66 | Africa |
59 | Surveys and Questionnaires |
59 | Africa South of the Sahara |
54 | Socioeconomic Factors |
49 | HIV Infections |
47 | Infant, Newborn |
46 | Sexual Behavior |
46 | Africa, Western |
44 | Anti-HIV Agents (therapeutic use) |
42 | HIV Infections (virology) |
39 | Disease |
38 | HIV Infections (diagnosis) |
38 | CD4 Lymphocyte Count |
37 | Virus Diseases |
36 | Retrospective Studies |
36 | HIV-1 (genetics) |
35 | Acquired Immunodeficiency Syndrome |
31 | Demography |
30 | Treatment Outcome |
30 | Molecular Sequence Data |
29 | South Africa (epidemiology) |
29 | Rural Population |
29 | HIV Infections (immunology) |
29 | Condoms (utilization) |
28 | HIV-1 |
27 | Seroepidemiologic Studies |
27 | Age Factors |
27 | Africa South of the Sahara (epidemiology) |
27 | Acquired Immunodeficiency Syndrome (epidemiology) |
26 | Population Surveillance |
26 | Phylogeny |
26 | Logistic Models |
26 | Cause of Death |
25 | Sex Factors |
25 | Risk-Taking |
25 | Family Planning Services |
25 | Acquired Immunodeficiency Syndrome (prevention & control) |
24 | Health Surveys |
24 | HIV Infections (blood) |
24 | Genotype |
23 | Time Factors |
23 | Case-Control Studies |
23 | Acquired Immunodeficiency Syndrome (psychology) |
22 | Sexual Behavior (psychology) |
22 | Incidence |
22 | Attitude to Health |
22 | Anti-Retroviral Agents (therapeutic use) |
21 | Viral Load |
21 | Prospective Studies |
21 | Economics |
20 | Sensitivity and Specificity |
20 | Interviews as Topic |
20 | Health Education |
20 | Educational Status |
19 | Qualitative Research |
19 | Health Planning |
19 | HIV-1 (isolation & purification) |
19 | HIV Seropositivity (epidemiology) |
19 | Focus Groups |
18 | Sex Work |
18 | Population |
18 | Behavior |
18 | Aged, 80 and over |
18 | Africa (epidemiology) |
17 | Sexually Transmitted Diseases (prevention & control) |
17 | Research |
17 | Program Evaluation |
17 | Poverty |
17 | Hospitals, Teaching |
17 | Hepatitis B (epidemiology) |
17 | HIV-1 (immunology) |
17 | HIV Seroprevalence |
17 | HIV Infections (mortality) |
17 | HIV Antibodies (blood) |
17 | Ghana (ethnology) |
16 | Stereotyping |
16 | Sexual Behavior (statistics & numerical data) |
16 | Sequence Analysis, DNA |
16 | Organization and Administration |
16 | Health Services Needs and Demand |
16 | Family Characteristics |
16 | Education |
16 | Counseling |
16 | Condoms |
16 | Comorbidity |
16 | Communication |
16 | Blood Donors |
16 | Antiretroviral Therapy, Highly Active |
15 | Social Support |
15 | Sexual Partners |
15 | Patient Acceptance of Health Care (statistics & numerical data) |
15 | Multivariate Analysis |
15 | Mass Screening |
15 | International Cooperation |
15 | Health Services Accessibility |
15 | HIV-2 (genetics) |
15 | Culture |
15 | Cohort Studies |
14 | Odds Ratio |
14 | HIV-1 (drug effects) |
14 | HIV-1 (classification) |
14 | Base Sequence |
14 | Anti-HIV Agents (administration & dosage) |
13 | World Health Organization |
13 | Residence Characteristics |
13 | Population Characteristics |
13 | Mass Screening (methods) |
13 | Infectious Disease Transmission, Vertical (prevention & control) |
13 | Health Behavior |
13 | HIV-2 |
13 | HIV Infections (genetics) |
13 | Enzyme-Linked Immunosorbent Assay |
13 | Emigration and Immigration |
13 | Coinfection (epidemiology) |
13 | Asia |
13 | Antiretroviral Therapy, Highly Active (methods) |
13 | Antibodies, Viral (blood) |
13 | Animals |
13 | AIDS-Related Opportunistic Infections (epidemiology) |
12 | Urban Population |
12 | Social Stigma |
12 | Risk Assessment |
12 | Reproducibility of Results |
12 | Peer Group |
12 | Longitudinal Studies |
12 | Infection |
12 | Hepatitis C (epidemiology) |
12 | Health Policy |
12 | Follow-Up Studies |
12 | Contraception |
12 | Age Distribution |
12 | Acquired Immunodeficiency Syndrome (transmission) |
11 | Sexually Transmitted Diseases |
11 | Sexual Behavior (ethnology) |
11 | Sex Distribution |
11 | Severity of Illness Index |
11 | RNA, Viral (blood) |
11 | Pregnancy Complications, Infectious (epidemiology) |
11 | Population Dynamics |
11 | Polymerase Chain Reaction |
11 | Organizations |
11 | Nigeria |
11 | Interpersonal Relations |
11 | Health |
11 | HIV-2 (immunology) |
11 | HIV Infections (economics) |
11 | Genetic Variation |
11 | Data Collection |
11 | Coinfection |
11 | Anti-HIV Agents (adverse effects) |
11 | Amino Acid Sequence |
11 | Africa, Western (epidemiology) |
11 | Africa, Eastern |
10 | Uganda |
10 | Tuberculosis, Pulmonary (complications) |
10 | Tuberculosis (epidemiology) |
10 | Tuberculosis (drug therapy) |
10 | Sexually Transmitted Diseases (epidemiology) |
10 | Rural Population (statistics & numerical data) |
10 | Rural Health |
10 | Reproductive Medicine |
10 | Regression Analysis |
10 | Pilot Projects |
10 | Perception |
10 | Mortality (trends) |
10 | Microbial Sensitivity Tests |
10 | HIV-2 (isolation & purification) |
10 | DNA, Viral (genetics) |
10 | CD4-Positive T-Lymphocytes (immunology) |
10 | Antitubercular Agents (therapeutic use) |
10 | Antimalarials (therapeutic use) |
10 | Algorithms |
9 | South Africa |
9 | Sexual Partners (psychology) |
9 | Risk |
9 | Recombination, Genetic |
9 | Prejudice |
9 | Politics |
9 | Malaria (prevention & control) |
9 | Kenya |
9 | Kenya (epidemiology) |
9 | Hepatitis B Surface Antigens (blood) |
9 | Health Personnel |
9 | Health Education (methods) |
9 | HIV Seropositivity (diagnosis) |
9 | HIV Infections (therapy) |
9 | HIV Infections (physiopathology) |
9 | HIV Infections (ethnology) |
9 | Double-Blind Method |
9 | Disease Outbreaks |
9 | Delivery of Health Care |
9 | Cost-Benefit Analysis |
9 | Blotting, Western |
9 | Blood Transfusion (adverse effects) |
9 | Autopsy |
9 | Adolescent Behavior (psychology) |
9 | Acquired Immunodeficiency Syndrome (immunology) |
9 | AIDS-Related Opportunistic Infections (microbiology) |
8 | Urban Health |
8 | United Nations |
8 | Survival Analysis |
8 | Sex Education |
8 | Program Development |
8 | Pregnancy Complications, Infectious (prevention & control) |
8 | Patient Acceptance of Health Care |
8 | Malaria (epidemiology) |
8 | International Agencies |
8 | Infectious Disease Transmission, Vertical |
8 | Hospitalization (statistics & numerical data) |
8 | Hepatitis C Antibodies (blood) |
8 | Hepatitis B (prevention & control) |
8 | HIV-1 (physiology) |
8 | HIV Seropositivity (immunology) |
8 | Global Health |
8 | Evaluation Studies as Topic |
8 | Drug Therapy, Combination |
8 | Databases, Factual |
8 | Data Collection (methods) |
8 | Body Mass Index |
8 | Adolescent Behavior |
8 | Acquired Immunodeficiency Syndrome (mortality) |
8 | Acquired Immunodeficiency Syndrome (ethnology) |
8 | Acquired Immunodeficiency Syndrome (drug therapy) |
7 | Zimbabwe |
7 | Zambia (epidemiology) |
7 | Women's Health |
7 | Viral Load (drug effects) |
7 | Tuberculosis (prevention & control) |
7 | Tuberculosis (complications) |
7 | Transients and Migrants |
7 | Tanzania (epidemiology) |
7 | Syphilis (epidemiology) |
7 | Social Class |
7 | Self Efficacy |
7 | Predictive Value of Tests |
7 | Patient Acceptance of Health Care (psychology) |
7 | Motivation |
7 | Molecular Epidemiology |
7 | Models, Statistical |
7 | Marriage |
7 | Hospitalization |
7 | Hepatitis C (transmission) |
7 | Health Status |
7 | Health Promotion (methods) |
7 | HIV-2 (classification) |
7 | HIV Seropositivity (virology) |
7 | HIV Seropositivity (psychology) |
7 | HIV Seropositivity (complications) |
7 | HIV Seropositivity (blood) |
7 | Financial Management |
7 | Disease Progression |
7 | Diet |
7 | Cultural Characteristics |
7 | Cluster Analysis |
7 | Burkina Faso |
7 | Attitude of Health Personnel |
7 | Antiretroviral Therapy, Highly Active (adverse effects) |
7 | Ambulatory Care Facilities |
7 | Africa, Northern |
7 | Acquired Immunodeficiency Syndrome (virology) |
7 | AIDS Serodiagnosis (utilization) |
6 | Urban Population (statistics & numerical data) |
6 | Unsafe Sex |
6 | Universities |
6 | United States |
6 | Tuberculosis (diagnosis) |
6 | Tanzania |
6 | Students (psychology) |
6 | Sequence Alignment |
6 | Sentinel Surveillance |
6 | Senegal |
6 | Seasons |
6 | Reverse Transcriptase Polymerase Chain Reaction |
6 | Research Design |
6 | Public Policy |
6 | Public Health |
6 | Proportional Hazards Models |
6 | Pregnancy Complications, Infectious (drug therapy) |
6 | Pregnancy Complications, Infectious (diagnosis) |
6 | Practice Guidelines as Topic |
6 | Population Surveillance (methods) |
6 | Phenotype |
6 | Mothers |
6 | Morbidity |
6 | Malaria (drug therapy) |
6 | Japan |
6 | Infectious Disease Transmission, Patient-to-Professional (prevention & control) |
6 | Infant Mortality |
6 | India |
6 | Hospitals |
6 | Hospital Mortality |
6 | Histoplasma (isolation & purification) |
6 | Hepatitis C (prevention & control) |
6 | Hepatitis B virus (isolation & purification) |
6 | Hepatitis B (transmission) |
6 | Hepatitis B (blood) |
6 | Hemoglobins (analysis) |
6 | Health Services Accessibility (statistics & numerical data) |
6 | HIV Infections (pathology) |
6 | HIV Envelope Protein gp120 (genetics) |
6 | Employment |
6 | Drug Combinations |
6 | Diagnosis, Differential |
6 | Developed Countries |
6 | DNA, Viral (analysis) |
6 | Cote d'Ivoire |
6 | Costs and Cost Analysis |
6 | Contraception Behavior (statistics & numerical data) |
6 | Condoms (statistics & numerical data) |
6 | Communicable Diseases (epidemiology) |
6 | Burkina Faso (epidemiology) |
6 | Antiviral Agents (therapeutic use) |
6 | Antifungal Agents (therapeutic use) |
6 | Anti-Bacterial Agents (therapeutic use) |
6 | Adenine (analogs & derivatives) |
6 | Adaptation, Psychological |
6 | Acquired Immunodeficiency Syndrome (microbiology) |
6 | AIDS-Related Opportunistic Infections (drug therapy) |
6 | AIDS-Related Opportunistic Infections (diagnosis) |
5 | United Kingdom |
5 | Tuberculosis, Pulmonary (epidemiology) |
5 | Tuberculosis, Pulmonary (diagnosis) |
5 | Truth Disclosure |
5 | Tenofovir |
5 | Simian Immunodeficiency Virus (genetics) |
5 | Self Report |
5 | Rotavirus Vaccines (immunology) |
5 | Rotavirus Vaccines (administration & dosage) |
5 | Rotavirus Infections (prevention & control) |
5 | Risk Reduction Behavior |
5 | Reverse Transcriptase Inhibitors (therapeutic use) |
5 | Religion |
5 | RNA, Viral (genetics) |
5 | Prognosis |
5 | Prenatal Care |
5 | Polymorphism, Single Nucleotide |
5 | Plant Extracts (pharmacology) |
5 | Peptide Fragments (genetics) |
5 | Outcome Assessment (Health Care) |
5 | Models, Theoretical |
5 | Medication Adherence (statistics & numerical data) |
5 | Mass Screening (statistics & numerical data) |
5 | Malawi |
5 | Lamivudine (therapeutic use) |
5 | Homosexuality, Male |
5 | History, 20th Century |
5 | Histoplasmosis (diagnosis) |
5 | Hepatitis B virus (genetics) |
5 | Hepatitis B (complications) |
5 | Health Services Research |
5 | Health Priorities |
5 | Health Care Surveys |
5 | HTLV-I Infections (epidemiology) |
5 | HIV |
5 | HIV Seropositivity |
5 | HIV Seropositivity (ethnology) |
5 | HIV (immunology) |
5 | Gender Identity |
5 | Food Supply |
5 | Drug Resistance, Viral |
5 | Decision Making |
5 | Counseling (utilization) |
5 | Cost of Illness |
5 | Community Participation |
5 | Coinfection (virology) |
5 | Coinfection (drug therapy) |
5 | Caregivers (psychology) |
5 | Blood-Borne Pathogens |
5 | Biomarkers (blood) |
5 | Autopsy (methods) |
5 | Asia (epidemiology) |
5 | Artemisinins (therapeutic use) |
5 | Anti-Infective Agents (therapeutic use) |
5 | Anti-HIV Agents (pharmacology) |
5 | Anemia (epidemiology) |
5 | Analysis of Variance |
5 | Administration, Oral |
5 | Acquired Immunodeficiency Syndrome (diagnosis) |
5 | Acquired Immunodeficiency Syndrome (complications) |
5 | AIDS Serodiagnosis |
5 | AIDS Serodiagnosis (methods) |
4 | Women |
4 | Women's Rights |
4 | Women (psychology) |
4 | Weight Gain |
4 | Vulnerable Populations |
4 | Vitamin A (administration & dosage) |
4 | Viremia |
4 | Viremia (epidemiology) |
4 | Vaccines, Attenuated (immunology) |
4 | Vaccines, Attenuated (administration & dosage) |
4 | Unsafe Sex (statistics & numerical data) |
4 | Unsafe Sex (psychology) |
4 | Tuberculosis, Pulmonary (mortality) |
4 | Tuberculosis, Pulmonary (microbiology) |
4 | Tuberculosis, Pulmonary (immunology) |
4 | Tuberculosis (psychology) |
4 | Tuberculosis (mortality) |
4 | Trimethoprim, Sulfamethoxazole Drug Combination (therapeutic use) |
4 | Travel |
4 | Sputum (microbiology) |
4 | Sexually Transmitted Diseases (psychology) |
4 | Sex Workers |
4 | Sex Workers (statistics & numerical data) |
4 | Sequence Homology, Nucleic Acid |
4 | Sequence Homology, Amino Acid |
4 | Schools |
4 | Sampling Studies |
4 | Safe Sex (statistics & numerical data) |
4 | Respiratory Tract Infections (virology) |
4 | Respiratory Tract Infections (epidemiology) |
4 | Reagent Kits, Diagnostic |
4 | RNA, Viral (analysis) |
4 | Quality of Life |
4 | Quality of Health Care |
4 | Prenatal Care (standards) |
4 | Pregnancy Outcome |
4 | Pregnancy Complications, Infectious |
4 | Pregnancy Complications, Infectious (virology) |
4 | Polymorphism, Genetic |
4 | Point-of-Care Systems |
4 | Patient Education as Topic |
4 | Parents (psychology) |
4 | Organophosphonates (administration & dosage) |
4 | Nutritional Status |
4 | Nigeria (epidemiology) |
4 | Needs Assessment |
4 | Nasopharynx (microbiology) |
4 | Mycobacterium tuberculosis (isolation & purification) |
4 | Mycobacterium tuberculosis (drug effects) |
4 | Mutation |
4 | Mothers (psychology) |
4 | Models, Psychological |
4 | Medication Adherence |
4 | Maternal Welfare |
4 | Maternal Mortality |
4 | Mass Media |
4 | Marriage (statistics & numerical data) |
4 | Mali (epidemiology) |
4 | Malaria (diagnosis) |
4 | Malaria (complications) |
4 | Malaria (blood) |
4 | Lamivudine (administration & dosage) |
4 | Intention |
4 | Information Services |
4 | Influenza, Human (epidemiology) |
4 | Income |
4 | Immunoglobulin M (blood) |
4 | Immunoglobulin G (blood) |
4 | Immunoenzyme Techniques |
4 | History, 21st Century |
4 | Herpesviridae Infections (epidemiology) |
4 | Herpes Genitalis (epidemiology) |
4 | Herpes Genitalis (drug therapy) |
4 | Hepatitis C (blood) |
4 | Hepatitis B (immunology) |
4 | Hepacivirus (immunology) |
4 | Health Personnel (education) |
4 | Health Care Costs |
4 | HIV Seropositivity (transmission) |
4 | HIV Seropositivity (drug therapy) |
4 | HIV Protease (genetics) |
4 | Guideline Adherence |
4 | Gonorrhea (epidemiology) |
4 | Genes, Viral |
4 | Gastroenteritis (prevention & control) |
4 | Financing, Organized |
4 | Fear |
4 | Far East |
4 | Enzyme-Linked Immunosorbent Assay (methods) |
4 | Developing Countries (statistics & numerical data) |
4 | Data Collection (standards) |
4 | DNA Primers |
4 | Cross-Cultural Comparison |
4 | Cooperative Behavior |